Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

HYD LLC for Cancer Research and Drug Development, corporate

HYD LLC for Cancer Research and Drug Development,

25.03.2021 - 16:04:10

HYD LLC for Cancer Research and Drug Development: HYD Substantiates the Science of Deuterium's Role in Cancer with Two New Peer-reviewed Articles

is proud of being at the leading edge of research and drug development at the submolecular level, of being a research and drug development company based on Hungarian discoveries and innovation. Our main aim is to serve the more efficient curation and prevention of diseases, and the improvement of quality of life, by novel products based on new scientific achievements.

About HYD LLC.

HYD LLC. was established in 1993 for the development and worldwide marketing of drugs and consumer products, that utilize the proprietary procedure, deuterium depletion. Since 1993, the company has been pioneering in research and drug development related to deuterium depletion and was worldwide the first to investigate the biological role and physiological importance of naturally occurring deuterium. The company's mission is to develop and register novel pharmaceutical and consumer products primarily for the treatment and prevention of tumorous diseases, and to open-up new ways of application of the method in further ranges of indication. The world's first deuterium-depleted antitumor medicine, Vetera-DDW-25(R) for veterinary application, was registered in Hungary in 1999. In 2000, the company brought the Preventa(R) deuterium-depleted drinking water products to the market. In 2012, Primus Capital closed a USD 2 Million investment in HYD Pharma Inc. The investment was used for validation of research results, and for set up the deuterium-depleted water (DDW) producing facility according to the GMP rules.Contact G?bor Somlyai PhD, CEO HYD LLC for Cancer Research and Drug Development Phone: +36 1 365 1660 mobil: +36 30 940 2311gsomlyai@hyd.huwww.hyd.huwww.deuteriumdepletion.comwww.preventa.orgwww.vetera.hu

?

25.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

1178572??25.03.2021?

@ dgap.de